HER-2/Neu Overexpression Does Not Predict Response to Neoadjuvant Chemotherapy or Prognosticate Survival in Patients with Locally Advanced Breast Cancer

This publication has 26 references indexed in Scilit:

• Expression of activated c-erbB-2 oncogene induces sensitivity to cisplatin in human gallbladder adenocarcinoma cells.
  2000
• Resistance to taxanes is induced by c-erbB-2 overexpression in human MCF-10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting type I protein kinase A
  International Journal of Cancer, 2000
• Prognostic relavance of cerbB2 expression following neoadjuvant chemotherapy in patients in a randomised trial of neoadjuvant versus adjuvant chemoendocrine therapy
  Breast Cancer Research and Treatment, 2000
• Comparison of Fluorescence In Situ Hybridization and Immunohistochemistry for the Evaluation of HER-2/neu in Breast Cancer
  Journal of Clinical Oncology, 1999
• erbB-2, p53, and Efficacy of Adjuvant Therapy in Lymph Node-Positive Breast Cancer
  JNCI Journal of the National Cancer Institute, 1998
• erbB-2 and Response to Doxorubicin in Patients With Axillary Lymph Node-Positive, Hormone Receptor- Negative Breast Cancer
  JNCI Journal of the National Cancer Institute, 1998
• c-erbB-2 Expression and Response to Adjuvant Therapy in Women with Node-Positive Early Breast Cancer
  New England Journal of Medicine, 1994
• Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer.
  Journal of Clinical Oncology, 1990
• Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
  Science, 1989
• CARCINOMA OF THE BREAST*
  Annals of Surgery, 1943